Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in Generalized Myasthenia Gravis
NCT06193889Phase 3Recruiting
- Sponsor
- Kyverna Therapeutics
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- CAR-T Cells
- Countries
- 6
01
Overview
A Phase 3 trial of mivocabtagene autoleucel in myasthenia gravis (MG), sponsored by Kyverna Therapeutics. Started Aug 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06193889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193889.